Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Vaxcyte, Inc.NASDAQ: PCVX
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q2 FY2026 selling, general & admin of $34.93M rose 9.0% year over year, behind the +14.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +48.1% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +39.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $34.93M+5.6% QoQ
- Last fiscal yearDec 2025
- $129.37M+39.3% YoY
- LTMJun 2026
- $132.67M+14.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.0% | -100.0% | -109.0 pp |
| 1 year | +39.3% | -100.0% | -139.3 pp |
| 3-year CAGR | +48.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 129.37M USD
- Year-over-year change
- +39.3%
- 4-year CAGR
- +50.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129.37M | +39.3% |
| FY2024 | 2024-12-31 | 92.9M | +53.1% |
| FY2023 | 2023-12-31 | 60.7M | +52.5% |
| FY2022 | 2022-12-31 | 39.81M | +57.6% |
| FY2021 | 2021-12-31 | 25.26M | — |
Selling, General & Admin vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.1% is the 2nd highest of 8, against a peer median of -11.6%.
- Over three fiscal years its annual growth of +48.1% compares with a peer median of +0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $13.72B USD | -1.7% | +0.3% | 21.5% | |
| LTM Jun 2026 | £9.2B GBP | -13.8% | +2.8% | 27.7% | |
| LTM Sep 2026 | $979M USD | -7.7% | -3.5% | 38.8% | |
| LTM Sep 2026 | $185.41M USD | +24.0% | +12.7% | 101.6% | |
| LTM Jun 2026 | $132.67M USD | +14.1% | +48.1% | — | |
| LTM Mar 2026 | $127.98M USD | -57.1% | -32.5% | 21.5% | |
| LTM Mar 2026 | €70.46M EUR | -23.0% | +9.1% | 45.1% | |
| LTM Mar 2026 | $69.19M USD | — | — | 105.6% | |
| LTM Mar 2026 | $43.57M USD | -11.6% | +0.0% | 96.1% | |
| Peer median (excluding PCVX) | — | -11.6% | +0.3% | 41.9% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M |
| Selling, General & Admin | 25.26M | 39.81M | 60.7M | 92.9M | 129.37M |
| Operating Expenses | 103.67M | 232.26M | 468.04M | 569.55M | 923.68M |
| Depreciation & Amortization | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| EBITDA | (96.61M) | (214.03M) | (392.1M) | (448.08M) | (741.77M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (103.67M) | (232.26M) | (468.04M) | (569.55M) | (923.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 344K | 8.36M | 62.91M | 109.99M | 119.72M |
| Interest Expense | 7K | 2K | 0 | 0 | 0 |
| Other Income / Expenses | 3.59M | 8.77M | 65.78M | 105.62M | 157.05M |
| Income Before Tax | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.93) | (3.44) | (4.14) | (3.80) | (5.63) |
| EPS (Diluted) | (1.93) | (3.44) | (4.14) | (3.80) | (5.63) |
| Weighted Avg Shares | 51.92M | 64.88M | 97.16M | 122M | 136.09M |
| Weighted Avg Shares (Diluted) | 51.92M | 64.88M | 97.16M | 122M | 136.09M |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.